Scientists Grow First Lab-Made Esophagus in Major Win
Researchers at Great Ormond Street Hospital and UCL have created the first functional lab-grown esophagus, successfully implanting it in pigs that could swallow normally without immunosuppression — a breakthrough that could transform treatment of esophageal atresia in newborns.
A Functioning Organ, Built From Scratch
A team of scientists at Great Ormond Street Hospital (GOSH) and University College London (UCL) has achieved what many in regenerative medicine considered a distant goal: building a fully functional esophagus in the laboratory and successfully implanting it in living animals. The results, published in Nature Biotechnology on March 20, 2026, mark the first time an engineered esophagus has restored normal swallowing in a growing large-animal model — without requiring immunosuppressive drugs.
The breakthrough, led by Professor Paolo De Coppi, a pediatric surgeon at UCL, targets a rare but devastating birth defect called long-gap esophageal atresia (LGOA), a condition in which the esophagus — the food pipe connecting the mouth to the stomach — fails to develop properly. Around 1 in 3,500 newborns worldwide is born with some form of esophageal atresia, and roughly 10% of those have the long-gap variant that makes straightforward surgical repair impossible.
How It Works: Scaffolds and Living Cells
The engineering process begins with a donor pig esophagus, which closely resembles a human one. Through a technique called decellularization, the team strips away all donor cells while preserving the organ's collagen and protein skeleton — its structural scaffold. This empty framework retains the shape, architecture, and mechanical properties of a natural esophagus.
Next, muscle precursor cells and fibroblasts are harvested from a small biopsy of the recipient animal and microinjected into the scaffold. The seeded construct then spends approximately two months in a bioreactor — a controlled environment with a constant flow of nutrients — where the recipient's cells colonize the scaffold and form a complete, living graft.
Remarkable Results in Pigs
The team implanted 2.5-centimeter engineered esophageal segments into minipigs to replace circumferential defects. Eight recipient animals recovered well. By the six-month mark, the grafts had developed functional muscle, nerves, and blood vessels. The bioengineered tissue contracted with sufficient strength and coordination to generate peristaltic movements — the wave-like muscle contractions that push food toward the stomach.
Crucially, because the implants were built from each recipient's own cells, no immunosuppression was needed. The tissue integrated fully into the digestive system, growing with the animals — a critical requirement for any treatment intended for newborns and infants.
Why This Matters for Newborns
Current treatments for long-gap esophageal atresia are far from ideal. Surgeons typically replace the missing esophageal segment with tissue from the stomach or colon — organs not designed for the job. These workarounds often lead to complications including acid reflux, feeding difficulties, and repeated surgeries throughout childhood.
"This is a major leap towards personalised regenerative treatments for children born with life-threatening esophageal conditions," Professor De Coppi said, adding that the approach "could pave the way for translation to other disease areas."
In the UK alone, around 180 babies are born with esophageal atresia each year. Globally, the condition affects an estimated 3 million newborns, with the long-gap form presenting the greatest clinical challenge.
Road to Human Trials
Despite the promising results, significant hurdles remain. The technology must progress through regulatory approvals and clinical trials before reaching patients. De Coppi's team hopes to begin first-in-human trials within five years, with a longer-term vision of creating banks of ready-to-use bioengineered organs that could be personalized for individual patients on demand.
While the realistic timeline for widespread clinical application may stretch to seven to twelve years, the study represents a definitive proof of concept — demonstrating that complex, multi-layered organs can be engineered to function in living, growing bodies. For families facing a diagnosis of long-gap esophageal atresia, it offers something that has been in short supply: genuine hope.
